<DOC>
	<DOCNO>NCT01813253</DOCNO>
	<brief_summary>This study evaluate overall survival nimotuzumab combination irinotecan compare irinotecan alone subject EGFR overexpressed advanced gastric gastroesophageal junction cancer .</brief_summary>
	<brief_title>Phase 3 Study Nimotuzumab Irinotecan Second Line With Advanced Recurrect Gastric Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>This randomize , open-label , Japan , Korea Taiwan collaborative , phase 3 study evaluate overall survival nimotuzumab combination irinotecan compare irinotecan alone subject EGFR overexpressed advanced gastric gastroesophageal junction cancer . Approximately 400 subject randomize 1:1 ratio receive irinotecan ( control group ) nimotuzumab irinotecan ( combination group ) . Nimotuzumab and/or irinotecan continue disease progression intolerable toxicity . Nimotuzumab administer 400 mg weekly intravenous infusion irinotecan administer 150 mg/m2 every 2 week intravenous infusion .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Advanced recurrent subject gastric gastroesophageal junction adenocarcinoma . 2 . Subjects experience disease progression first line within 6 month last dose first line therapy . The first line regimen must contain 5fluorouracil base agent platinum agent . 3 . Subjects EGFR overexpression ( 2+ 3+ IHC ) 1 . Subjects receive irinotecan 2 . Subjects receive EGFRdirected therapy 3 . Other active malignancy within last 5 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>second line</keyword>
</DOC>